Merck COVID-19 Drug Could Gain Emergency Use Authorization

Merck & Co. has made waves by claiming one of its antiviral drugs, molnupiravir, could reduce hospitalizations for COVID-19 by roughly half — as has the company’s announced plans to seek emergency use authorization (EUA) from the FDA for the drug.

Experts are optimistic that the drug could be the first of several new therapeutics and prophylactics for COVID-19 — but caution that molnupiravir may not be right for every patient, requires scaled-up production and could be more costly in the commercial market than many expect.

© 2022 MMIT
Peter Johnson

Peter Johnson

Peter has been a reporter for nearly a decade. Before joining AIS Health, Peter covered a wide variety of topics in his hometown of Seattle, where he continues to live. Peter’s work has appeared in publications including The Atlantic and The Stranger. Peter attended Colby College.

Related Posts

workers-prepping-infusion-drug
May 12

Major PBMs Look Ahead to 2023 for Biosimilars Boom

READ MORE
wall-street-sign
May 12

Centene Plans to Sell Magellan Rx, PANTHERx Rare for $2.8 Billion

READ MORE
pills-and-dollars
May 12

Study: With High Prices, Rebate Revenue Is Growing for PBMs

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today